IQVIA (NYSE:IQV) Reaches New 1-Year Low – Should You Sell?

IQVIA Holdings Inc. (NYSE:IQV) shares reached a new 52-week low on Thursday . The stock traded as low as $135.39 and last traded at $137.00, with a volume of 890416 shares trading hands. The stock had previously closed at $137.29.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Barclays reduced their target price on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, Robert W. Baird cut their target price on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

IQVIA Trading Down 0.8%

The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $23.69 billion, a P/E ratio of 18.26, a PEG ratio of 1.99 and a beta of 1.34. The business has a 50 day moving average of $155.33 and a 200-day moving average of $183.63.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the firm earned $2.54 earnings per share. The firm’s revenue was up 2.5% compared to the same quarter last year. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Howard Capital Management Inc. boosted its position in IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares in the last quarter. Continuum Advisory LLC lifted its stake in shares of IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 64 shares during the last quarter. Ballentine Partners LLC boosted its holdings in shares of IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after acquiring an additional 69 shares in the last quarter. Independent Advisor Alliance grew its position in IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after acquiring an additional 72 shares during the last quarter. Finally, Magnolia Capital Advisors LLC increased its holdings in IQVIA by 2.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock worth $516,000 after purchasing an additional 74 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.